TrialInvestigational new drugs2022

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.

Julian Taugner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.